CD33 and myelodysplastic syndrome: Cheng et al. developed a CD33/CD3 bispecific T cell splice agent, AMV564, which effectively depleted CD33hi MDSCs in MDS and improved T-cell antitumor activity, and its combination with immune checkpoint inhibitors improved patient resistance to AMV564 [148].